Contrasting Q2 Results for Insulin Pump Makers Tandem and Insulet

Tandem Diabetes Care and Insulet, insulin pump makers, reported contrasting Q2 results, with Tandem's shares down 3.3% and Insulet's up 6.7%. Tandem's Q2 revenue fell short of estimates, while Insulet's revenue beat expectations. Medtronic, the larger rival, traded flat.

In the latest quarterly financial reports, Tandem Diabetes Care, Inc. (TNDM) and Insulet Corporation (PODD) presented contrasting results. While Tandem's shares declined by 3.3% following the announcement, Insulet's shares surged by 6.7%. The two insulin pump makers reported vastly different revenue performances, with Tandem's revenue falling short of estimates and Insulet's revenue beating expectations. Meanwhile, Medtronic plc (MDT), a larger rival, traded flat.

Tandem Diabetes Care

Tandem Diabetes Care reported a quarterly loss of $0.48 per share, surpassing the Zacks Consensus Estimate of a loss of $0.40. This compares to a loss of $0.47 per share a year ago. The company's revenue for the quarter ended June 2025 was $240.68 million, surpassing the Zacks Consensus Estimate by 0.87%. Over the last four quarters, Tandem has topped consensus revenue estimates three times [1].

Insulet Corporation

Insulet Corporation, known for its Omnipod® brand, reported significant growth in revenue. The company's revenue for the second quarter of 2025 was $649.1 million, a 32.9% increase year-over-year, exceeding the high end of the company's guidance range. Omnipod revenue reached $639.0 million, growing by 33.0% year-over-year. Insulet's adjusted net income was $83.7 million, or $1.17 per diluted share, compared to $38.3 million, or $0.55 per diluted share, in the prior year [2].

Medtronic plc

Medtronic plc, the largest medical device company, traded flat following its quarterly report. The company's stock has surged 10.6% over the past year, but it has lagged behind the S&P 500 Index ($SPX), which has surged by 21.1% during the same period. Among 30 analysts covering MDT stock, the consensus rating is a "Moderate Buy," with 13 "Strong Buy" ratings. The mean price target of $95.83 represents a 7.2% premium to MDT's current price levels [3].

Conclusion

The contrasting Q2 results from Tandem Diabetes Care and Insulet Corporation highlight the diverse performance within the insulin pump market. While Tandem's revenue fell short of estimates, Insulet's revenue beat expectations, leading to a significant difference in share price movements. Medtronic, the larger rival, held steady, reflecting a cautious market response to the latest quarterly reports.

References

[1] https://www.nasdaq.com/articles/tandem-diabetes-care-inc-tndm-reports-q2-loss-beats-revenue-estimates
[2] https://www.tradingview.com/news/tradingview:3aefcce0006a8:0-insulet-corporation-q2-2025-financial-results/
[3] https://www.barchart.com/story/news/33957247/are-wall-street-analysts-bullish-on-medtronic-stock